Dear Reader,
Happy Tuesday!
Today I want to talk about weight loss drugs.
I don’t know if you saw in the news last week that Medicare and Medicaid are starting to consider covering these new GLP-1 drugs made by Eli Lilly and Novo Nordisk.
This is amazing, really.
We recommended these as investments a couple years back before the drugs were approved.
(We just updated our report with new picks right here.)
We’ve done very well with our weight-loss drug recommendations, obviously, because these things have just gone berserk.
===
This Weight-Loss Drug “Loophole” Could Make Investors Very Wealthy
Thanks to a rare FDA “loophole,” we know the exact dates two small cap stocks could win FDA approval of a new class of weight-loss drugs…
Creating a once-in-a-lifetime profit window for investors.
Get the full story here>>>
===
We’re up, 200-300% with Altimmune…
We made a few hundred percent on Viking Therapeutics…
Basically doubled our money with Eli Lilly and saw gains with Novo Nordisk, too.
We got in so early and predicted that Medicare would back these drugs and that would create an explosion in gains, which happened.
So the first four stocks we recommended in our report on weight loss drugs did very well.
We took a lot of profits and we’ve since been sitting back watching how the GLP-1 drug industry (i.e. Ozempic) played out.
And we’ve recently updated our report with some very compelling stocks to buy for the “second wave” of this weight-loss/Ozempic megatrend. You can get access to our new report and picks right here.
To give you an idea of how big these drugs are going to be…
Morgan Stanley estimates there will be more of these treatments taken every single year (250 million!) than Lipitor, Viagra, and Metformin, combined.
When we think about the obesity problems in this country it’s easy to understand why this will be a massive blockbuster.
When you think about how much it costs Medicare and Medicaid to treat high blood pressure, heart issues, cancers, so many obesity-related health conditions…
And when you see the astonishing results these new GLP-1 drugs like Ozempic have produced treating these problems…
It’s not surprising the U.S. government is now pushing to actually pay for these drugs.
Because when you think about what it could save our medical systems over time, and that one of the hallmarks of the incoming Trump administration is to cut costs, it seems like a no-brainer.
The average obesity-related healthcare per person is $5,000 a year. The drug costs $3,000 a year. That’s a $2,000 savings per person, basically.
This is great news for American wellness, for the U.S. economy, and especially for investors in these groundbreaking, life-saving drugs.
Tidak ada komentar:
Posting Komentar